Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Randomized Phase 2 and Phase 3 Studies of the First Triple-Combination Drug

Main Article Content

Linda Stein Gold, MD
Henry Ford Hospital, Detroit, MI

Leon H. Kircik, MD
Icahn School of Medicine at Mount Sinai, New York, NY and Indiana University Medical Center, Indianapolis, IN and Physicians Skin Care, PLLC, DermResearch, PLLC, and Skin Sciences, PLLC, Louisville, KY

Emil A Tanghetti, MD
Center for Dermatology and Laser Surgery, Sacramento, CA

Hilary Baldwin, MD
The Acne Treatment and Research Center, Brooklyn, NY and Robert Wood Johnson University Hospital, New Brunswick, NJ

Zoe D. Draelos, MD
Dermatology Consulting Services, PLLC, High Point, NC

Michael Gold, MD
Tennessee Clinical Research Center, Nashville, TN

Edward Lain, MD, MBA
Austin Institute for Clinical Research, Austin, TX

David M Pariser, MD
Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA

Neil Sadick, MD
Weill Cornell Medical College and Sadick Dermatology, New York, NY

Radhakrishnan Pillai, PhD
Bausch Health US, LLC, Petaluma, CA

Varsha Bhatt, PhD
Bausch Health US, LLC, Petaluma, CA

Keywords

acne, topical

References

N/A

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.159

Article Details

How to Cite
Stein Gold, L., Kircik, L., Tanghetti, E., Baldwin, H., Draelos, Z., Gold, M. ., Lain, E. ., Pariser, D., Sadick, N., Pillai, R. ., & Bhatt, V. (2023). Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Randomized Phase 2 and Phase 3 Studies of the First Triple-Combination Drug. SKIN The Journal of Cutaneous Medicine, 7(2), s159. https://doi.org/10.25251/skin.7.supp.159
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Acne & Rosacea
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

1 2 3 4 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>